$AMRZ

Forrest Nollaig purchased $100K of AMRZ

Forrest Nollaig (Chief Mktg & Corp Affairs Off) purchased 2,000 shares of Amrize Ltd (AMRZ) at $50.25 ($0.10M total) on 2026-05-22.

Original reporting
SEC EDGAR · Forrest Nollaig
Published May 26, 2026, 5:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMRZ
Bullish
medium confidence
Mentioned
$AMRZ
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZBullishMed
01

Why it matters

This disclosure may slightly improve sentiment toward AMRZ, but it does not constitute a fundamental catalyst (no earnings, deal, or regulatory update provided).

02

Market read

Traders may use the insider buy as a minor bullish input, but expect limited price reaction absent additional news.

03

What to watch

Transaction size (~$100.5k) is relatively small; without follow-on buys/sells or guidance, signal strength is likely weak.

Relevance 7/10Timing: Immediate (filed 2026-05-26; trade date 2026-05-22) for short-term sentiment checks.

Background

The filing is an SEC Form 4 insider transaction: Forrest Nollaig (Chief Mktg & Corp Affairs Officer) bought AMRZ shares in an open-market purchase, not under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$AMRZBullishMedium confidence
Context

Amrize Ltd (AMRZ) disclosed an officer open-market purchase of 2,000 shares at $50.25 on 2026-05-22 via SEC Form 4.

Expected impact

Likely limited near-term impact; could add incremental support if market treats it as confidence signal.

Evidence & confidence

Form 4 shows direct officer buying and no 10b5-1 plan, yet the article provides no operational catalyst or size context beyond ~$100.5k.

Market effects

Minimal—this is company-specific insider activity with no stated sector-wide catalyst.

None indicated; no geographic or cross-border developments mentioned.

None indicated; transaction is a routine SEC insider disclosure.

Counterpoint

Insider buys can be routine liquidity/compensation-related actions and may not reflect new fundamentals, especially without additional corroborating news.

Key entities

  • Amrize Ltd

    AMRZ insider disclosed an open-market purchase of 2,000 shares at $50.25 on 2026-05-22.

  • Forrest Nollaig

    Chief Mktg & Corp Affairs Officer; purchased 2,000 AMRZ shares directly.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.